CRL
- Trade priority
- not ranked
- Data coverage
- 55%
- Setup
- no setup · 2026-10-02
- News
- positive
- Next catalyst
- Earnings in 21 sessions
Trade plan
No trade plan: the strategy has no valid setup for this symbol (trend or relative-strength condition fails (relative_strength_20)).
Your portfolio · San
- Profile
- Sanequity 2,000.00 USD · whole shares
- Current holding
- noneno open position in this profile
- Recommended quantity
- —no pending entry to size
- Risk budget
- 10.000.5% of 2,000.00
- Portfolio risk
- 0.00 opencap 2%
- Exposure
- 0 / 3 positionsHealthcare: 0 / 2 · 0.00 of 1,000.00 cap
- Cash impact
- 2,000.00derived from the ledger
- Eligibility
- AVOIDsame as the strategy view
Entry, stop, targets and R:R are strategy-owned and identical for every profile; only this portfolio's quantity, risk, exposure and cash differ. Manage profiles · record a fill
Why this action
Technical
- trend or relative-strength condition fails (relative_strength_20)
- RS20 vs SPY -0.6%, vs QQQ -5.5%
Options
- volume 0.13× the 20D baseline (activity_accelerating) · selected contracts only, delayed
News and events
- news context positive (31 canonical items in window)
- earnings 2026-11-03 (21 sessions, finnhub); event risk low
- regulatory · high · positive: Pharmaceutical Impurity Synthesis and Isolation Services Report: Capitalize on a $2.1 Bil
- earnings · high · positive: Charles River Laboratories International Reiterates FY26 Revenue, Non-GAAP Earnings Outloo
- insider · low · unknown: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: 4 filed
- analyst · low · neutral: Charles River Laboratories (CRL) Stock Fair Value Rises After Analyst Day Target Increases
Market and risk
- regime RISK ON: SPY: trend UP, volatility NORMAL; QQQ: trend UP, volatility NORMAL
Chart
Indicator history is derived from the stored bars with the accepted M3 functions (WORKSTATION_SERIES_V1); the scanner’s persisted values remain authoritative. Reconciliation at the scan session: 8 match.
Trade priority
Not ranked: only valid setups and gated setups enter the trade-priority ranking.
- technical readinessn/a
- structure quality10/10
- relative strength-0/15
- participation4/10
- risk rewardn/a
- news context10/10
- event risk5/5
- urgency3/5
operational attention priority not a return forecast. Missing inputs lower coverage, never the score.
Setup evidence · PRE_BREAKOUT_V1
- Setup state
- NO_SETUP
- Resistance
- 298.9
- Distance
- 2.91%
- Close
- 290.19
- SMA50
- 276.07
- SMA150 / SMA200
- 214.03 / 209.97
- RSI14
- 55.6
- EMA20 extension
- 0.44 ATR
- RS20 vs SPY
- -0.6%
- RS20 vs QQQ
- -5.5%
Hard requirements · 7/8 passed
- PASSConfirmed resistanceresistance=298.9013 exists eligible=true
- PASSDistance to resistancedistance_pct=2.9144 · resistance=298.9013 · close=290.19 inclusive_between min=0 · max=3
- PASSClose above SMA50close=290.19 · sma50=276.0668 > right_operand=sma50
- PASSSMA150 ≥ SMA200sma150=214.0315 · sma200=209.9702 >= right_operand=sma200
- PASSRSI14 bandrsi14=55.624 inclusive_between min=50 · max=70
- PASSEMA20 extension (ATR)extension_atr=0.438 · close=290.19 · ema20=286.0224 · atr14=9.5158 <= max=1.5
- FAILRS20 vs SPY or QQQSPY=-0.0062 · QQQ=-0.0552 OR > SPY=0 · QQQ=0
- PASSResistance qualitydistinct_touches=3 policy_and_minimum_touches min=2
Supporting evidence · 3/6 passed
- PASSATR compressioncurrent_atr_pct=0.0328 · median_previous_60_atr_pct=0.0359 · ratio=0.9135 < right_operand=median_previous_60_atr_pct
- PASSVolume contractionrecent_volume=726,227.5638 · baseline_volume=964,112.2506 · ratio=0.7533 < max=0.85
- FAILHigher lowslow_1=276.6575 · low_2=280.91 · low_3=267.27 low_3 > low_2 > low_1 required_pivots=3
- PASSFull MA alignmentsma50=276.0668 · sma150=214.0315 · sma200=209.9702 sma50 > sma150 > sma200
- FAILRS20 vs SPY positiveSPY=-0.0062 > min=0
- FAILRS20 vs QQQ positiveQQQ=-0.0552 > min=0
PRE_BREAKOUT_V1 · scan run 412 · session 2026-10-02 · evaluated as of 2026-10-04T13:22:43.415154Z. Supporting evidence never changes the trigger; UNKNOWN is never collapsed into false.
Intelligence timeline
- 2026-10-0220:27 UTC
- 2026-10-0219:06 UTCPrice targets for Charles River Laboratories International have shifted higher in recent research, with several firms now pointing to a range between US$219 and US$340, alongside a new fair value estimate of US$305. That cluster of higher targets aligns with more constructive analyst commentary after the company’s investor and analyst days, as firms factor in the updated long range plan and revise
- 2026-10-0207:13 UTC
- 2026-09-3013:28 UTCAnimal model demand is rising with drug and vaccine research. CRISPR, AI and humanized models offer opportunities, while ethical scrutiny spurs humane alternatives.Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "Animal Model - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global animal model market was estimated at US$2.1 billion in 2025 and is projected to
- 2026-09-3012:40 UTCHere is how Aveanna Healthcare (AVAH) and Charles River Laboratories (CRL) have performed compared to their sector so far this year.
- 2026-09-3011:00 UTCCharles River (NYSE:CRL) has outperformed the market over the past 15 years by 3.32% on an annualized basis producing an average annual return of 16.72%. Currently, Charles River has a market capitalization of $15.15
- 2026-09-3008:42 UTCUBS analyst Kevin Caliendo reinstates Charles River (NYSE:CRL) with a Buy and announces $357 price target.
- 2026-09-2916:11 UTCCooke & Bieler, an investment management firm, released its second-quarter investor letter for “Mid Cap Value Equity Strategy.” The letter can be downloaded here. U.S. equities rallied significantly in Q2, driven by shifting geopolitical risks and strong investor appetite for high-beta stocks, particularly in the tech sector, contributing to the S&P 500® and Nasdaq’s best […]
- 2026-09-2915:52 UTCStricter quality rules, complex biologics and outsourcing are driving demand for impurity isolation, synthesis and analytics, creating opportunities for specialized labs and CROs.Dublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- "Pharmaceutical Impurity Synthesis and Isolation Services - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global pharmaceutical impur
- 2026-09-2915:51 UTCAI, machine learning, cloud analytics and multi-omics are accelerating drug discovery, enabling targeted, personalized therapies while reducing development time, cost and risk.Dublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- "Computer-Aided Drug Discovery - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global computer-aided drug discovery market was estimated
- 2026-09-2911:33 UTCEngagement of a leading global contract research organization strengthens the analytical foundation supporting EL-22 and EL-32 as the programs advance toward an IND-enabling development frameworkBuilds on NorthStrive Biosciences’ expanding manufacturing and characterization capabilities behind its engineered probiotic platform targeting muscle preservation, including for patients on GLP-1 weight l
- 2026-09-2908:07 UTCBoost ROI by matching models to research goals, standardizing studies, investing in quality data and training, integrating validated AI and alternatives, and aligning global partnershipsDublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- "Experimental Animal Model Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. This market research report examines the global Experim
- 2026-09-2810:05 UTCJefferies analyst David Windley maintains Charles River (NYSE:CRL) with a Buy and raises the price target from $305 to $340.
- 2026-09-2720:55 UTCCharles River Laboratories has outperformed the broader market over the past year, while analysts remain bullish on the company’s outlook.
- 2026-09-2601:02 UTCCharles River Laboratories International (NYSE:CRL) outlined a strategy to accelerate growth, expand margins and modernize its operations during its 2026 Investor Day, setting financial targets through 2030 that include 5% to 7% organic revenue growth, an approximately 24% non-GAAP operating margin
- 2026-09-2508:30 UTCCharles River Laboratories has doubled over the past year, outperforming despite regulatory and AI-related concerns. Click for this CRL stock update.
- 2026-09-2507:26 UTCBaird analyst Eric Coldwell maintains Charles River (NYSE:CRL) with a Outperform and raises the price target from $291 to $334.
- 2026-09-2506:09 UTCCharles River Laboratories International has seen its share price move sharply over the past year, and that kind of run naturally raises a question for you as an investor. Are the cash flows that the business can generate enough to support where the stock now trades? The stock has returned 102.3% over the past 12 months, which puts real pressure on the case that its current valuation can still be
- 2026-09-2423:04 UTCShares of lab services company Charles River Laboratories (NYSE:CRL) jumped 5.7% in the afternoon session after the company outlined long-term financial targets through 2030 and raised its 2026 earnings outlook at its Investor Day.
- 2026-09-2413:01 UTCOpportunities center on AI-enabled decentralized trials, therapeutic specialization, global patient recruitment, regulatory support, real-world evidence and integrated partnerships.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "Contract Research Organization Services Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The Contract Research Organization Services Ma
- 2026-09-2412:58 UTCOpportunities include validated AI, cloud safety platforms, real-world evidence, integrated pharmacovigilance, patient-centric reporting and expansion in emerging markets.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "Drug Safety Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The global Drug Safety Market research report examines growth trends, regulatory dev
- 2026-09-2412:12 UTC
- 2026-09-2412:00 UTCWILMINGTON, Mass., September 24, 2026--Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day
- 2026-09-2410:01 UTCNasdaq fell 150+ points, while Everpure jumped 14% after unveiling growth plans and a FY2028 outlook; other stocks also gained.
- 2026-09-2409:37 UTC2026-09-24. The following slide deck was published by Charles River Laboratories International, Inc.
- 2026-09-2408:08 UTCCharles River Laboratories International, Inc. (NYSE: CRL) will host its 2026 Investor Day today, September 24, 2026, starting at 9:00 a.m. ET.The Company is also introducing the following long-term financial targets
- 2026-09-2408:02 UTCPharma R&D outsourcing is rising as CROs use AI, genomics and advanced screening to cut costs, accelerate discovery, improve compliance and support targeted therapies.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "Drug Discovery Services - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Drug Discovery Services was estimated at US$10.8 Billio
- 2026-09-0813:59 UTC
- 2026-08-2720:21 UTC
- 2026-08-2520:10 UTC
- 2026-08-2020:31 UTC
- hidden4 provider-tagged items never name the company and are kept as context only.
canonical items of the last 10 sessions; analyst/industry/macro commentary and social sources excluded from the direction tally; gating uses tier 1-3 HIGH items within 3 (negative) / 2 (unknown direction) sessions
Catalysts and filings
| Event | Date | In | Materiality | Source |
|---|---|---|---|---|
| Earnings (before the open) | 2026-11-03 | 21 sessions | high | finnhub · Tier 3 · provider |
Options activity
- Session volume
- 31
- 5D baseline
- 380
- 20D baseline
- 232
- Volume / 20D
- 0.13x
- Call / put volume
- 22 / 9
- Call / put ratio
- 2.44
- Top-3 contract share
- 81%
- Top expiration
- 2026-10-16 100%
Activity trend · last 32 sessions
| Session | Volume | 5D | 20D | / 20D |
|---|---|---|---|---|
| 2026-09-24 | 625 | 414 | 179 | 3.50x |
| 2026-09-25 | 304 | 473 | 210 | 1.45x |
| 2026-09-28 | 24 | 410 | 225 | 0.11x |
| 2026-09-29 | 133 | 390 | 226 | 0.59x |
| 2026-09-30 | 31 | 380 | 232 | 0.13x |
Call vs put volume
Expiration concentration
Contract concentration
Top contracts · session 2026-09-30
| Contract | Type | Strike | Expiration | DTE | Volume | 5D avg | 20D avg | / 20D | Return | Moneyness |
|---|---|---|---|---|---|---|---|---|---|---|
| O:CRL261016C00280000 | CALL | 280 | 2026-10-16 | 16 | 16 | 79 | insufficient history | insufficient history | 0.4% | ITM (5.4%) |
| O:CRL261016P00290000 | PUT | 290 | 2026-10-16 | 16 | 5 | 84 | insufficient history | insufficient history | 2.7% | OTM (1.7%) |
| O:CRL261016C00300000 | CALL | 300 | 2026-10-16 | 16 | 4 | 22 | insufficient history | insufficient history | -4.2% | OTM (-1.7%) |
| O:CRL261016P00270000 | PUT | 270 | 2026-10-16 | 16 | 2 | 31 | insufficient history | insufficient history | 1.9% | OTM (9.3%) |
| O:CRL261016C00290000 | CALL | 290 | 2026-10-16 | 16 | 1 | 41 | insufficient history | insufficient history | 0.0% | ITM (1.7%) |
| O:CRL261016C00310000 | CALL | 310 | 2026-10-16 | 16 | 1 | 25 | insufficient history | insufficient history | 0.0% | OTM (-4.8%) |
| O:CRL261016P00260000 | PUT | 260 | 2026-10-16 | 16 | 1 | 17 | insufficient history | insufficient history | 0.0% | OTM (13.5%) |
| O:CRL261016P00280000 | PUT | 280 | 2026-10-16 | 16 | 1 | 48 | insufficient history | insufficient history | 0.0% | OTM (5.4%) |
OPTIONS_SELECTION_M9_V1 selected contracts only · provider capability DELAYED · delayed · Top 15 selected contracts by session volume; 5D/20D averages use strictly prior sessions (M10), INSUFFICIENT_HISTORY is shown, never zero.
M13 observations for this session
- Technical setup present (PRE_BREAKOUT_V1): FALSE
- Technical and options context share a session: FALSE
- Activity above its own 20-session baseline: FALSE
- Activity below its own 20-session baseline: TRUE
- Recent 5-session baseline above 20-session baseline: TRUE
- Recent 5-session baseline below 20-session baseline: FALSE
- Volume concentrated in top 3 contracts: TRUE
- Volume concentrated in one expiration: TRUE
- Calls carry most session volume: TRUE
- Puts carry most session volume: FALSE
- Call and put volume roughly balanced: FALSE
- Enrichment data (snapshot/OI/IV/Greeks) available: FALSE
- Enrichment data unavailable: TRUE
- Real flow data unavailable: TRUE
- Flow events present in replay window: NOT_EVALUABLE
Flow
Flow engine is ready. Trades and Quotes are not available with the current provider capabilities; this area populates automatically from the same M11 engine when real persisted facts exist. Synthetic fixture flow is never shown.
Evidence alerts
| Category | Alert | Previous | Current | Sessions | Workflow | Actions |
|---|---|---|---|---|---|---|
| Changed | Distance to resistance narrowed | 4.03 | 2.91 | 2026-10-01 → 2026-10-02 | New | |
| Fading | Options activity vs 20D baseline fell | 0.59 | 0.13 | 2026-09-29 → 2026-09-30 | New | |
| Changed | Call / put volume mix changed | 0.92 | 0.71 | 2026-09-29 → 2026-09-30 | New |
Decision trace
- setup_eligibleFAILNO_SETUP: failed relative_strength_20failed_conditions=relative_strength_20
- finalPASSAVOID
Snapshot history: 2026-09-30 ARMED
Actions are generated from the configured trading strategy and current available market/intelligence data. They are not guarantees of future performance.